(NASDAQ: IMRX) Immuneering's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.57%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.16%.
Immuneering's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast IMRX's revenue for 2028 to be $514,214,256, with the lowest IMRX revenue forecast at $514,214,256, and the highest IMRX revenue forecast at $514,214,256. On average, 1 Wall Street analysts forecast IMRX's revenue for 2029 to be $5,853,726,073, with the lowest IMRX revenue forecast at $5,853,726,073, and the highest IMRX revenue forecast at $5,853,726,073.
In 2030, IMRX is forecast to generate $11,949,917,638 in revenue, with the lowest revenue forecast at $11,949,917,638 and the highest revenue forecast at $11,949,917,638.